» Articles » PMID: 19164499

Psychiatrists' Attitude Towards and Knowledge of Clozapine Treatment

Overview
Publisher Sage Publications
Specialty Pharmacology
Date 2009 Jan 24
PMID 19164499
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Clozapine is, in most countries, underutilized and the initiation of clozapine is often delayed. The purpose of this study is to investigate the reasons for the delay and the underutilization of clozapine. One hundred psychiatrists were interviewed by phone. The interview was a structured interview with questions regarding attitude to, knowledge of and experiences with clozapine. Forty-eight (48%) psychiatrists had treatment responsibility of fewer than five patients treated with clozapine and 31 of the interviewed psychiatrists (31%) had started clozapine within the last 3 months. Seven psychiatrists (7%) had never prescribed clozapine despite the fact that they had been working more than five years in general psychiatry. Sixty-four psychiatrists (64%) would rather combine two antipsychotics than use clozapine. Sixty-six psychiatrists (66%) believed that patients treated with clozapine were less satisfied with their treatment when compared with those treated with other atypical antipsychotics. Many psychiatrists are reluctant to use clozapine and this might be due to less experience and knowledge of clozapine. A reason for the low awareness of clozapine's properties might be that clozapine is now a generic drug, and therefore, the marketing and education in using the drug is sparse.

Citing Articles

What is the current scope of research assessing patients' and clinicians' perspectives on clozapine treatment? A comprehensive scoping review.

Jakobsen M, Schaug J, Storebo O, Austin S, Nielsen J, Simonsen E BMJ Open. 2025; 15(1):e085956.

PMID: 39819922 PMC: 11751990. DOI: 10.1136/bmjopen-2024-085956.


Multi-level barriers and facilitators to implementing evidence-based antipsychotics in the treatment of early-phase schizophrenia.

Carroll A, Robinson D, Kane J, Kordon A, Bannon J, Walunas T Front Health Serv. 2024; 4:1385398.

PMID: 39469435 PMC: 11513390. DOI: 10.3389/frhs.2024.1385398.


The risk of diabetes and HbA1c deterioration during antipsychotic drug treatment: A Danish two-cohort study among patients with first-episode schizophrenia.

Madsen N, Sorensen M, Danielsen A, Hojlund M, Rohde C, Kohler-Forsberg O Acta Psychiatr Scand. 2024; 151(1):69-80.

PMID: 39379169 PMC: 11608811. DOI: 10.1111/acps.13760.


Patients' Experiences of Clozapine for Treatment-Resistant Schizophrenia: A Systematic Review.

Parkes S, Mantell B, Oloyede E, Blackman G Schizophr Bull Open. 2024; 3(1):sgac042.

PMID: 39144802 PMC: 11205966. DOI: 10.1093/schizbullopen/sgac042.


Prescribing Patterns of Psychotropic Medications for Common Psychiatric Disorders in a Mental Health Hospital in Tabuk.

Ali M, Amirthalingam P, Veeramani V, Alasiri A, Alsalimi M, Alatawi F Cureus. 2024; 16(2):e54927.

PMID: 38544646 PMC: 10971419. DOI: 10.7759/cureus.54927.